CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus — Stella

View on ClinicalTrials.gov

Recruiting

Back to SLE trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

Key details

Phase

Early testing / Safety & dosing

Sponsor

Children's Hospital of Philadelphia

Enrollment target

~24 participants

Started

May 2025

Primary completion

February 2030

Age range

12 Years – 29 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.